BridgeBio have significantly advanced its progress of the novel therapy for ATTR-CM, employing the compound. Initial patient information reveals potential benefits for patients suffering by the debilitating condition. https://attrcm098627.timeblog.net/78049043/bridgebio-advances-cardiac-amyloidosis-therapy-through-the-therapy